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ORIGINAL ARTICLE
Ability of Platelet-Derived Extracellular Vesicles to Promote
Neutrophil-Endothelial Cell Interactions
Sahithi J. Kuravi,1,2 Paul Harrison,2,3 George Ed Rainger,1 and Gerard B. Nash 1,2,4
Abstract— We tested the ability of platelet-derived extracellular vesicles (PEV) to promote
adhesion of flowing neutrophils to endothelial cells (EC). PEV were collected from platelets
stimulated with collagen-related peptide, and differential centrifugation was used to collect
larger vesicles enriched for platelet membrane microvesicles (PMV) or smaller vesicles
enriched for platelet exosomes (Pexo). Vesicle binding and resultant activation of neutrophils
and EC were assessed by flow cytometry. Flow-based adhesion assays assessed binding of
neutrophils directly to deposited vesicles or to EC, after neutrophils or EC had been treated
with vesicles. PEV bound efficiently to neutrophils or EC, with resultant upregulation of
activation markers. Binding was Ca++-dependent and dominantly mediated by CD62P for
neutrophils or by integrins for EC. Deposited PEV supported mainly transient attachments of
flowing neutrophils through CD62P and some stable adhesion through CXC-chemokines.
Neutrophil adhesion to ECwas promoted when either cell was pre-treated with PEV, although
the effect was less prominent when EC were pre-activated with tumor necrosis factor-α. The
pro-adhesive effects on neutrophils could largely be attributed to the larger PMV rather than
Pexo. Thus, surface-bound PEV can capture flowing neutrophils, while PEV also activate
neutrophils and EC to promote interactions. PEV may potentiate inflammatory responses
after tissue injury.
KEYWORDS: platelets; extracellular vesicles; neutrophils; endothelial cells; cell adhesion.
INTRODUCTION
Platelet extracellular vesicles (PEV) are sub-micron
particles released from activated, apoptotic, or stored pla-
telets [1–3]. They form a major portion of the normal EV
population found in the plasma in the circulation [4], with
raised numbers in various pathologies, including trauma,
venous thromboembolism, rheumatoid arthritis, ischemia,
and uremia (reviewed in [5]). PEV carry a diverse cargo of
proteins, with constituents depending on the platelet acti-
vation process [6, 7]. Their content can be transferred to
other cells through pathways involving endocytosis, mac-
ropinocytosis, phagocytosis, and lipid raft-mediated fusion
and internalization (reviewed by Mulcahy et al. [8]). PEV
can thus mediate crosstalk between cells by transferring
active agents, for instance influencing haemostatic and
inflammatory responses [9–11].
The role(s) of PEV in inflammation are facilitated by
their capacity to bind to leukocytes and endothelial cells
(EC) [9, 12, 13]. Uptake and bioactivity of PEV may
depend on the binding proteins expressed on the PEVand
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recipient cells and on specific agents in their cargo. Phos-
phatidyl serine is typically exposed on the PEV surface,
along with adhesive glycoproteins including GP1b
(CD42b), GPIIbIIIa (αIIbβ3-integrin; CD41CD61), β1-
integrin (CD29), and P-selectin (CD62P), while cargo
carried includes proinflammatory cytokines and chemo-
kines such as interleukin (IL)-1β, IL-8 (CXCL8), IL-6,
and RANTES (CCL5) [13–21]. The effector role of PEV
in inflammation may arise from promotion of leukocyte-
endothelial interactions. EV uptake has been shown to
upregulate activation markers, such as CD11b on neutro-
phils (polymorphonuclear cells, PMN) and CD54/ICAM-1
on EC, and increase leukocyte adhesion to EC in vitro and
in vivo [13, 15, 22, 23]. However, the mechanisms by
which PEV might bind to PMN and EC, and the means
by which PEVmight promote PMN recruitment from flow
are not well-defined to date.
PEV are not homogenous and can be broadly clas-
sified into plasma membrane-derived microvesicles
(PMV; diameter about 100–1000 nm) and platelet exo-
somes (Pexo; about 40–100 nm) [24–26]. Pexo are in-
tracellular nanovesicles released through exocytosis
[26], while PMV are shed from the plasma membrane
and usually characterized by exposed phosphatidylserine
[24–27]. Proteomic studies have analyzed the different
protein contents of these PEV fractions [28–31]. In ad-
dition to their difference in size, PMV and Pexo were
shown to have complicated molecular profiles with some
overlap, which may impart diverse functions in physio-
logical and pathological processes [7, 31–34]. However,
studies so far have usually characterized the effects of
total PEV populations in inflammatory processes, with
only the occasional study of the role of PMV or Pexo
separately [26].
Here, we aimed to investigate the ability of PEV to
promote interactions when PMN were perfused over EC.
The EC and/or PMN were treated with PEV before the
PMNwere perfused, while in some studies, a surface was
coated with PEV to test the direct ability of deposited
PEV to capture PMN. Cell-binding kinetics for PEVand
consequent upregulation of activation markers on PMN
and EC were also studied, as were the effects of inhib-
itors of adhesion molecules and chemokines likely to
influence interactions between the different vesicles
and cells. Some studies were repeated for PEV that had
been centrifugally fractionated to enrich for PMV or
Pexo. In this way, we aimed to gain insight into the
potential pro-inflammatory roles of PEV acting on




Antibodies used for label and immunofluorescence
studies were as follows: FITC-conjugated anti-CD41
(clone 5B12, Dako, UK), anti-CD42b (clone HIP1, BD
Pharmingen, UK), anti-CD62P (P-selectin, clone AK-4,
BD Pharmingen, UK), and anti-CD106 (VCAM-1, clone
51-10C9, BD Pharmingen, UK); PE conjugated anti-
CD62E (E-selectin, clone 1.2B6, Sigma-Aldrich,UK),
anti-CD31 (clone 9G11, R&D systems, UK), and anti-
CD11b (αm-integrin, clone 2LPM19c, Dako, UK); APC-
conjugated anti-CD54 (ICAM-1, clone HA58, BD
Pharmingen, UK) and anti-CD144 (VE-Cadherin, clone
16B1, ebioscience, UK); and control FITC- and PE-
conjugated IgG1 (Dako, UK) or APC-conjugated IgG1
(BD Pharmingen, UK). All were used at suppliers’ recom-
mended dilutions.
Function blocking antibodies were as follows: anti-
CD541 (20 μg/ml, clone 8.4A6 Sigma-Aldrich, UK),
anti-CD106 (20 μg/ml, clone BBIG-V1, R&D Systems,
UK), anti-CD62E (20 μg/ml, clone H4/18, BD Pharmin-
gen, UK), anti-CD11b (10 μg/ml, clone ICRF44, Ebio-
science, UK), anti-CXCL5 (ENA-78, 10 μg/ml, clone
33160, R&D systems, UK), anti-CXCR1 & 2 (4 μg/ml,
clones 501 & 19, respectively, Abcam, UK), anti-CD42b
(GP1b, 10 μg/ml, clone SZ2, Beckman Coulter, UK), anti-
CD62P (10 μg/ml, clone G1, Ancell), anti-CD29 (β1-
integrin, 10 μg/ml, Mab 13, BD Pharmingen, UK), CD61
(β3-integrin, 10 μg/ml, clone SZ21, Beckman Coulter,
UK), anti-CD51 (αv-integrin, 10 μg/ml, clone L230, Enzo
Lifesciences, UK), and anti-CD41/CD61 (GPIIb/IIIa,
αIIBβ3-integrin 10 μg/ml, clone c7E3, Janssen Biologics
BV, Netherlands). Additional inhibitors were the peptide
Arg-Gly-Asp-Ser (RGDS, 0.5 mM, Sigma-Aldrich, UK)
and EDTA (10 mM, Sigma-Aldrich, UK).
Isolation and Label of Platelets and Generation of PEV
Blood samples were obtained from healthy, adult
volunteers, with written, informed consent and approval
from the University of Birmingham Local Ethical Review
Committee. Studies were performed in accordancewith the
ethical standards as laid down in the 1964 Declaration of
Helsinki. Venous blood was collected into tubes with anti-
coagulant citrate phosphate dextrose adenine solution
(CPDA, 1:9 with blood v/v, Sigma-Aldrich, UK). Platelet
isolation was as described previously [35]. Blood was
centrifuged at 250 g for 15 min at RT with added theoph-
ylline (7 mM, Sigma-Aldrich, UK) to maintain a resting
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state. The supernatant platelet-rich plasma (PRP) was col-
lected into a polypropylene tube and diluted with phos-
phate buffered saline without Ca/Mg (PBS, Sigma) with
0.15% bovine serum albumin (BSA, Sigma) and 7-mM
theophylline (PBSA-T) and centrifuged at 800 g for 15min
to pellet the resting platelets. Supernatant was discarded
and pelleted platelets were resuspended in PBS with BSA.
Platelet concentration was measured with a Coulter T-540
and adjusted to 3 × 108 platelets/ml in PBS with BSA, with
Ca/Mg (PBSA), or in PBSA-T if they were to be labeled.
For labeling, platelets in PBSA-Twere incubated with
FITC-conjugated anti-CD41, anti-CD42b, anti-CD62P, or
IgG1 control for 30 min in the dark at room temperature.
Alternatively, platelets were stained with the cell mem-
brane label PKH67 (Sigma) according to the manufac-
turer’s instructions. The platelets were washed free of
unbound antibody or dye by resuspending in 15mls of
PBSA-T without Ca/Mg and centrifuged at 800 g for
15 min to pellet the platelets. The pellet was resuspended
in PBSA at a concentration of 3 × 108 platelets/ml.
PEV were generated using labeled or unlabeled
platelets at 3 × 108/ml as required. Initially, platelets
were incubated for 30 min at 37 °C with 1 μg/ml of
crosslinked collagen related peptide (CRP-XL) (from
Professor Farndale, University of Cambridge, UK) or
thrombin receptor-activating peptide (TRAP, 10 μM,
Bachem AG, Switzerland) or in the absence of agonist
as a control. Platelets were removed by centrifugation
at 2000 g for 20 min followed by transfer of superna-
tant to a fresh Eppendorf, which was centrifuged for
2 min at 13,000 g to remove residual platelets [36, 37].
The supernatant contained PEV, which can be sub-
classified into platelet microvesicles (PMV) and plate-
let exosomes (Pexo). To enrich for PMV, 1-ml super-
natant was transferred into a new tube and centrifuged
for 45 min at 16,500 g at 4 °C. The pelleted larger
vesicles were collected and resuspended in 1-ml
PBSA. The supernatant was then transferred to a fresh
tube and subjected to centrifugation for 1 h at
100,000 g at 4 °C. To obtain enriched Pexo, the super-
natant was discarded and the vesicles resuspended in 1-
ml PBSA. PEV suspensions or other prepared samples
were frozen at − 20 °C until further use.
Characterization of PEV by Nanoparticle Tracking
Analysis (NTA) and Flow Cytometry
Size distribution and concentration of PEV and cen-
trifugal fractions were determined using a Nanosight
LM10 (Malvern Instruments, UK) equipped with NTA
software 2.2 as described [38]. The minimum size detected
was ~ 50 nm. Samples were diluted with filtered PBS to
achieve an optimum particle concentration of 108–109/ml.
Three hundred microliters of sample was introduced into a
chamber held on a light microscope, which was
illuminated by laser at an angle to the optical axis of the
microscope. A digital camera attached to the microscope
visualized the scattered light from particles, and images
were captured at a rate of 30/s for 60 s. Individual particles
were counted and tracked, and their Brownian motion
analyzed to yield their velocity and hence diameter. The
recording yielded the frequency distribution of vesicle
sizes and an estimate of the total number of vesicles/ml.
PEV derived from labeled platelets were analyzed on
a BD Accuri C6 flow cytometer (BD, Oxford, UK). The
gating window for counting PEV and discriminating
against background noise was set using forward and side
scatter plots for Megamix fluorescent polystyrene beads
(BioCytex, France) of diameters 500 nm, 900 nm, and
3 μm as described [38]. EV counts were taken from the
gate that included 500- and 900-nm megamix beads. Sam-
ples were analyzed at a low flow rate (14 μl/min) until
2000 positive events were collected in the EV gate. The
total EV numbers were acquired from counts in the micro-
vesicle gate defined as above, for a known sample volume.
The label-specific counts were obtained from fluorescent
signals for the different labels analyzed one at a time, for
particles that fell in light scatter gate and were positively
labeled compared to fluorescent isotype controls.
The PEV counts and particle diameters analyzed by
NTA, and the counts analyzed by flow cytometry were
similar for platelets treated with TRAP of CRP-XL (data
not shown). Values for CRP-XL are reported below and for
further studies CRP-XL was used, to avoid transfer of a
stimulatory agent (TRAP) along with PEV when treating
PMN and/or EC.
Isolation of PMN and Human Umbilical Vein
Endothelial Cells
PMN were isolated from venous blood from con-
sented, healthy, adult volunteers collected into EDTA tubes
(Sarstedt Ltd., Leicester, UK). PMNwere isolated by over-
laying blood on density gradients of histopaque 1077 over
histopaque 1119 (Sigma-Aldrich, UK) as described [39].
Collected PMNwere washed using PBSA, counted using a
Cellometer auto T4 cell counter (Nexcelom Bioscience
Ltd., Manchester, UK), and adjusted to 106 cells/ml in
PBSA.
Inflammatory Activity of Platelet Extracellular Vesicles
Human umbilical vein endothelial cells (HUVEC)
were isolated from umbilical cords by collagenase treat-
ment as described previously [40]. Umbilical cords were
obtained from the Human Biomaterials Resource Centre
(University of Birmingham) after informed consent.
HUVEC were cultured at 37 °C with 5% CO2 in M199
supplemented with 20% fetal calf serum, 10-ng/mL epi-
dermal growth factor, 35-μg/mL gentamicin, 1-μg/ml hy-
drocortisone (Sigma-Aldrich, UK), and 2.5-μg/mL
amphotericin B (Life Technologies, CA). Confluent pri-
mary HUVEC were detached with trypsin/EDTA (Sigma),
washed, and reseeded into 24 well plates (Corning, UK) or
into flow channels (Ibidi u-Slide VI (0.4), Thistle Scientif-
ic, UK) for studies of vesicle uptake or flow-based adhe-
sion experiments, respectively.
Binding Kinetics of PEV to PMN or HUVEC
Isolated PMN were incubated with CD41-labeled
PEVor PKH-labeled PEV at a concentration of 109 PEV/
ml in PBSA in a test tube placed on roller mixer at 37 °C.
At chosen times, PMN were washed from unbound PEV
by centrifuging at 400 g for 5 min and the PMN pellet was
labeled with PE-conjugated anti-CD11b for 30 min in the
dark at room temperature. CD11b labeled PMN were
washed from unbound antibody by pelleting as described
above and were fixed in 100-μl 2% (w/v) formaldehyde.
Fixed PMN were analyzed using a BD Accuri C6 flow
cytometer to determine the percentage positively stained
with PEV label and CD11b. Alternatively, images were
captured using a Zeiss LSM780 confocal microscope. To
investigate the mechanism of binding of PEV, monoclonal
antibodies against CD11b, GP1b, CD62P, CXCR3,
GPIIb3a or control IgG1, or RGDS, or EDTAwere added
either to PMN or PEV prior to their mixing and incubation.
Confluent HUVEC grown in 24 well plates were
incubated with CD41-labeled PEV at a concentration of
109 PEV/well in PBSA. At chosen times, HUVEC were
washed from unbound PEVusing PBSA and the cells were
labeled for EC marker APC-conjugated CD144 for 30 min
at 37 °C. The labeled cells were subjected to Accutase
treatment (Stem pro dissociation reagent, Gibco, UK) to
dissociate cells into suspension and centrifuged at 400 g for
5 min to remove enzyme activity and unbound antibody.
Labeled cells were fixed in 100-μl 2% (w/v) formaldehyde
and analyzed using a BD Accuri C6 flow cytometer to
determine the percentage positively stained with PEV label
and CD 144. Alternatively, images were captured using a
Zeiss LSM780 confocal microscope. To investigate the
mechanism of binding of PEV, monoclonal antibodies
against CD51, CD29, CD61, GPIIbIIIa, CD62P or control
IgG1, or RGDS or EDTAwere added either to HUVEC or
PEV prior to their mixing and incubation.
Detection of HUVEC or PMN Activation
Surface expression of HUVEC adhesion molecules
was assessed by label with fluorescent antibodies against
ICAM-1, VCAM-1, or E-selectin, followed by analysis by
a BD Accuri C6 flow cytometer to measure percentage
positive and median fluorescence intensity (MFI). PMN
activation was assessed from the MFI for CD11b label,
using the same samples as those described above for
assessing percentage positive for PEV markers.
Flow-Based PMN Adhesion Assays
To assess the direct ability of PEV on a surface to
capture PMN under flow, PEV were incubated for 1 h at
37 °C in microslides (glass capillaries with rectangular
cross-section 300 μm× 3 mm and 50-mm long; Camlab
Ltd., Cambridge, UK) that had been treated with amino-
propyltriethoxysilane (Sigma-Aldrich, UK) as described
[39]. To assess adhesion of PMN to EC, HUVEC sub-
cultured into ibidi μ-slides were treated with PEVadded to
culture medium 1:1 v/v, for 1, 4, or 24 h. In some experi-
ments, HUVEC were treated at the same time with 1, 5, or
100-U/ml tumor necrosis factor-α (TNF; Sigma) for 4 h.
PMN adhesion was analyzed in a flow-based assay as
described previously [35, 40]. Briefly, ibidi μ-slides or
microslides were placed on the stage of a phase-contrast
video microscope at 37 °C and connected to a Harvard
syringe pump set to a flow rate equivalent to a wall shear
stress of 0.025, 0.05, or 0.1 Pa. The other end was
connected via an electronic valve to allow perfusion of
PBSA or PMN suspended in PBSA. After flushing with
PBSA, PMNwere perfused for 4 min followed by washout
of non-adherent cells with PBSA. A series of video record-
ings were made along the centerlines of the flow chambers
and analyzed offline using Image Pro software (Image-
ProPlus, UK). After washout, the number of adherent
PMN was counted from the images and converted to
PMN/mm2/106 perfused based on the known field size,
sample concentration, and flow rate. To analyze transient
capture events during inflow, PMN that were visible and
formed short-lived attachments on the PEV-coated surface
during perfusion were counted in a fixed period, converted
to number/mm2/min, and multiplied by the area of the
chamber to obtain a value for total cells captured from
flow/min. In some experiments, PMN were pre-treated
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with PEV at 109/ml for 30 min at 37 °C before perfusion
over surfaces in the continued presence of the PEV.
In some experiments, PEV deposited on the micro-
slides were pre-treated with blocking antibodies against
CD62P or CXCL5 for 30 min prior to the perfusion of
PMN. Alternatively PMN were treated with antibodies
against CXCR1 or CXCR2 for 30 min at 37 °C. PMN
were washed by centrifugation at 400 g for 5 min prior to
the perfusion over PEV or HUVEC. In others, HUVEC
were pretreated with blocking antibodies against ICAM-1,
VCAM-1, E-selectin, or CXCL5 for 4 h along with PEV
incubation at 37 °C.
Chemokine Detection in PEV Supernatant
Supernatants containing PEV or centrifugal fractions
were screened for soluble mediators using a multiplex bead
immunoassay (R&D Systems, UK), with or without pre-
filtration through 0.2-μm pore filters or 100-kD molecular
cutoff filters (Millipore, UK). The immunoassay measured
levels of CXCL8, CCL5, CXCL5, and CXCL1 (growth-
related oncogene, GRO-α).
Statistical Analysis
Variation between multiple treatments was evaluated
using analysis of variance (ANOVA), followed where ap-
propriate with post hoc comparisons to control by Dunnett
test or between conditions by Bonferroni test. Effects of
single treatments were analyzed by paired t test compared
to controls. Data is expressed as the mean ± SEM, and a p
value of < 0.05 was considered statistically significant.
RESULTS
Characterization of Vesicles Derived from Activated
Platelets
PEV were generated from platelets suspended at 3 ×
108/ml stimulated by CRP-XL and isolated by double
centrifugation. The total PEV count analyzed by NTA
was 1.25 ± 0.34 × 1010 particles/ml (mean ± SEM; n =
19). The size distribution of PEV is shown in Fig. 1a;
diameter varied between 50 and 700 nm and the mode
was between 100 and 150 nm (Fig. 1a). Flow cytometry
counted 1.5 ± × 106 particles/ml (mean ± SEM; n = 8) in a
gate which incorporating 500- and 900-nm calibration
beads. PEV from platelets labeled with fluorescent anti-
bodies and analyzed by flow cytometry proved to be 70 ±
3% positive for CD41, 37 ± 3% positive for CD42b, and
only 18 ± 4% positive for CD62P (mean ± SEM for at least
six experiments). Subsequent studies of binding of PEV to
cells utilized CD41 as the label. In some experiments,
where platelets were labeled with PKH67, 91 ± 4% of
PEV were positively labeled (mean ± SEM, n = 5).
We also analyzed the size of PEVenriched for platelet
microvesicles by centrifuging the PEV for 45 min at
16,500 g and PEVenriched for platelet exosomes collected
by centrifuging the supernatant from that preparation for
Fig. 1. Vesicle diameter analyzed by NTA. Frequency distributions of p-
article diameter measured for: (a) PEV, n = 19, (b) PEVlarge enriched for
PMV, n = 5, (c) PEVsmall enriched for Pexo, n = 5. Data are pooled from
the n separate samples of vesicles prepared from platelets activated by
CRP-XL.
Inflammatory Activity of Platelet Extracellular Vesicles
1 h at 100,000 g. Since the exosome-rich fraction could not
be shown to be exclusively of endosomal origin, the two
fractions were labeled as large or small PEV (PEVlarge and
PEVsmall, respectively). NTA showed that the former
contained a larger proportion of particles extending to a
larger diameter ~ 500 nm, and the latter were restricted to
particles < 250 nm (Fig. 1b, c). There was not a clear
separation into two, non-overlapping populations with re-
spect to size.
Characterization of Binding of PEV to PMN
We mixed isolated PMN with PEV pre-labeled with
antibody against CD41 or dye PKH67, in the continued
presence of labeled antibody to CD11b (αm-integrin), to
assess the kinetics of uptake of PEV label by the PMN and
their level of expression of CD11b by flow cytometry.
Within 2 min, a high proportion of PMN were positive for
CD41 or PKH67, with further slower increase over about
15 min to ~ 80% positive (Fig. 2a). There was initially a
higher proportion positive with PKH67, but final values
were similar for CD41. Further studies used this more
specific label unless stated otherwise. Examining the effect
of varying the number of PEVadded, after 30-min incuba-
tion, the proportion of PMN positively labeled was insen-
sitive to the number added between 109 and 1010 (data not
shown), but the MFI increased steadily over this range
(Fig. 2b). Confocal microscopy indicated that intracellular
localization of many PEV within the PMN occurred by
30 min (Fig. 2c, d). Interestingly, during the binding of
PEV to PMN, there was also a steady increase in the level
of CD11b expressed on the surface of the PMN (Fig. 2e).
There was approximately 50% increase in MFI of CD11b
expression by 2 min, with the increase becoming 90% by
15 min. Thus, PEV binding appeared to activate the PMN.
Next, we investigated the binding mechanisms of
PEV to PMN by using blocking reagents. Pretreatment of
PMN with EDTA or antibody against CD62P significantly
reduced PEV binding by ~ 60 or ~70%, respectively
(Fig. 2f). RGDS peptide did not reduce binding. Antibod-
ies against GPIb or GPIIbIIIa tended to reduce binding but
not significantly (Fig. 2f), but a blocking antibody against
αm-integrin, CD11b (distinct from that used for fluores-
cence label) did significantly inhibit binding. Thus, PEV-
PMN interactions required Ca+2/Mg++, consistent with the
binding requirements of CD62P and CD11b.
Characterization of Binding of PEV to HUVEC
Binding of PEV to HUVEC was characterized by the
uptake of CD41+ PEVand flow cytometry. Here, we found
that 43 ± 6.5% of HUVEC had bound labeled PEV within
1 h, increasing to 51 ± 4% by 4 h and remaining constant at
~ 50% at 24 h (data are mean ± SEM, n = 7). Confocal
images indicate the intracellular localization of the PEV
in HUVECmonolayer at 4 h (Fig. 3a, b). We also analyzed
activation of HUVEC in response to PEV binding, based
on expression of adhesion molecules typically up-
regulated in inflammation. We detected that PEV induced
significant increase in surface expression of ICAM-1 and
E-selectin by 4 h, and an increase in VCAM-1 that did not
reach significance (p = 0.085) (Fig. 3c).
Mechanisms of PEV binding to HUVEC were tested
using blocking reagents and antibodies. EDTA significant-
ly reduced PEV binding by ~ 80%, but blockade of P-
selectin did not reduce binding (Fig. 3d). RGDS reduced
binding by nearly 70%. Blocking GPIIbIIIa had little ef-
fect, while blocking β1-, β3-, or αν-integrins (CD21,
CD61, CD51, respectively) each caused a significant re-
duction of binding by about 20% (Fig. 3c). These results
suggest that Ca+2/Mg++-dependent integrin interactions
played a major role in PEV binding to HUVEC.
Ability of PEV to Directly Recruit Flowing PMN
To test whether PEV could directly support recruitment
of PMN on a surface, glass microslides were coated with
PEV (1 × 1010/ml) and perfused with PMN at a wall shear
stress of 0.1 Pa. Video observations demonstrated multiple
short-lived adhesive capture events (> 9500 PMN captured
from flow/slide/min), compared to none on BSA coating
(Fig. 4a). The duration of transient attachments was 0.25 ±
0.03 s (mean ± SEM; n = 34 cells). We also observed further
~ 50% increase in PMN capture from flow when PMNwere
pretreated and perfused along with PEV over the PEV-
treated surface (Fig. 4a). The adhesion was again transient,
with PMN hopping across the surface with a capture time
increased to 0.4 ± 0.07 s (mean ± SEM n = 19 cells). Only a
small number of captured PMN adhered firmly, although
this number did increase when PMN were pretreated with
PEV (Fig. 4b). In two experiments, increasing the number of
PEV used to coat the microslides from 1 × 1010/ml to 2.5 ×
1010/ml also increased the number of short attachments
(from 4550 to 18,700 PMN/slide/min) and especially the
number firmly adherent (from 4 to 116 PMN/mm2/106
perfused) (means, n = 2). We also tested the effect of
perfusing PMN at lower shear stresses of 0.05 or 0.025 Pa.
The rate of capture events was not significantly altered,
although still higher for surfaces coated with PEV
(Fig. 4c). However, there were significantly more stably
adherent PMN at the lower stresses Fig. 4d).
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Examining the mechanisms involved in direct recruit-
ment of PMN by PEV, blockade of CD62P on PEV caused
> 60% inhibition of capture events and stable adhesion
(Fig. 4e, f). Blocking CXCR1, CXCR2, or both had vari-
able and non-significant effects on capture. While the
individual agents also tended to reduce stable adhesion,
only the combination reached a statistically significant
effect, with adhesion reduced by > 80%.
Analysis of the PEV suspensions by chemokine array
revealed presence of the CXC chemokines CXCL1 (GRO-
α), CXCL5 (ENA-78), and CXCL8 (IL-8), which operate
through CXCR1 and CXCR2 (Fig. 5). CXCL5was present
Fig. 2. Characterization of binding of PEV to PMN. (a) Percentage of PMN positively stained with PEV from platelets labeled with anti-CD41 (n = 6) or
PKH67 (n = 4) for different incubation times. One-way ANOVA showed a significant effect of time for each treatment (both p < 0.01); p < 0.01 compared to
zero time at all subsequent times by Dunnett test. (b) Effect of PEV concentration onMFI of PMN incubated for 30 min with PEV (n = 3). One-wayANOVA
showed a significant effect of concentration (p < 0.01). ** = p < 0.01 compared to zero PEV by Dunnett test. (c), (d) Representative confocal microscope
images of PMN either untreated (c) (control) or incubated (d) for 30 min with PEV from platelets labeled with FITC-conjugated anti-CD41 (green). PMN
were also labeled with anti-CD11b (red) and propidium iodide (blue). (e) Change in surface expression of CD11b on PMNwith time during incubation with
PEV; MFI determined by flow cytometry (n = 6). One-way ANOVA showed a significant effect of time (p < 0.01). * = p < 0.05, ** = p < 0.01 compared to
zero time by Dunnett test. (f) Effects of inhibitory agents or function-blocking antibodies on labeling of PMN with PEV from platelets labeled with anti-
CD41. PMN were incubated with PEV for 30 min in the presence of EDTA (n = 7), anti-CD62P (n = 9), RGDS (n = 7), anti-GP1b (n = 10), anti-GPIIbIIIa
(n = 5), or anti-CD11b (n = 9). One-way ANOVA showed a significant effect of inhibitory treatments (p < 0.01). ** = p < 0.01 compared to none by Dunnett
test. All data are mean ± SEM from n experiments.
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at high levels (~ 7 ng/ml) in the bioactive range, while
CXCL1 and CXCL8 were much lower at about 0.3 ng/ml.
To test whether these were associated with PEV, we filtered
PEV through 0.2-μm pore or 100-kD MW cutoff column
filters. Levels of CXCL5 and CXCL8, but not CXCL1
tended to be reduced by 0.2-μm filters, but this effect was
not statistically significant. Each chemokine was reduced
after filtration through the 100-kD filter (Fig. 5). Thus,
chemokines were borne by a range of sizes of PEV, with
a relatively small proportion being soluble and able to pass
through the cutoff filter with size much greater than the
chemokines themselves (~ 10 kD). These results suggest
that PEV borne CD62P and CXC-chemokines played roles
in surface-bound PEV-mediated PMN capture and firm
adhesion.
Ability of PEV to Promote PMN Recruitment by
HUVEC
To determine whether PEV could induce adhesion of
PMN to HUVEC, we first treated HUVEC with PEV for
1 h and then perfused PMN at a wall shear stress of 0.05 Pa.
Video observations demonstrated significant increase in
PMN capture from flow compared to untreated HUVEC,
which did not support transient attachments (Fig. 6a). PEV-
treated HUVEC also supported a greater number of firmly
adherent PMN, about twice as many as observed for un-
treated HUVEC (Fig. 6b). Interestingly, perfusion of PMN
along with PEV also caused short-lived attachments on
HUVEC which had not themselves been pre-treated with
PEV, although this form of treatment did not significantly
increase firm adhesion (Fig. 6a, b). Moreover, when treated
PMN were perfused over treated HUVEC, levels of cap-
ture or firm adhesion was similar or modestly increased
compared the values for experiments where only the
HUVEC had been treated with PEV (Fig. 6a, b). These
results suggest that only a short exposure of HUVEC to
PEV is required to cause formation of short-lived attach-
ments, although longer may be required to induce firm
adhesion.
Studies of PMN perfused over HUVEC were thus
repeated for different periods of incubation of the HUVEC
with PEV (1, 4, and 24 h). Pretreatment ofHUVECwith PEV
for 1 or 4 h caused significant increases in inflow capture, but
Fig. 3. Characterization of binding of PEV to HUVEC. (a), (b) Representative confocal microscopy images of HUVEC either untreated (a) (control) or
incubated (b) for 4 h with PEV from platelets labeled with FITC-conjugated anti-CD41 (green). HUVEC were also labeled with anti-CD144 (red) and
propidium iodide (blue). (c) Changes in surface expression of VCAM-1, ICAM-1, or CD62E on HUVEC after incubation with PEV for 4 h (determined by
MFI relative to untreated control) (n = 6). $ = p = 0.054, * = p < 0.05 ** = p < 0.001 compared to control by paired t test. (d) Effects of inhibitory agents or
function-blocking antibodies on labeling of HUVEC with PEV from platelets labeled with anti-CD41. HUVEC were incubated with PEV for 4 h in the
presence of EDTA (n = 7), anti-CD62P (n = 10), RGDS (n = 7), anti GPIIbIIIa (n = 8), anti-CD29 (n = 11), anti-CD61 (n = 11), or anti-CD51 (n = 10). One-
way ANOVA showed a significant effect of inhibitory treatments (p < 0.01). * = p < 0.05, ** = p < 0.01 compared to none by Dunnett test. All data are mean
± SEM from n experiments.
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Fig. 4. Ability of PEV to directly support PMN recruitment from flow. (a) Comparison of the number of transient capture events for PMN perfused at a wall
shear stress of 0.1 Pa over surfaces coated with BSA or PEV. Neutrophils were perfused alone (n = 13) or with PEVadded to the cell suspension (n = 5). (b)
Stably adherent PMN on surfaces coated with BSA or PEV, after perfusion under the same conditions, and washout of non-adherent cells. One-way ANOVA
showed a significant effect of treatment combinations on capture events and stable adhesion (p < 0.01 in each case). * = p < 0.01, ** = p < 0.01 by Bonferroni
test. (c), (d) Effect of varying wall shear stress on transient capture events (c) or stable adhesion (d) for PMN perfused over surfaces coated with BSA or PEV
(n = 6). Two-way ANOVA showed a significant effect of surface treatment (p < 0.01) but not shear stress on capture events and significant effects of surface
treatment and of shear stress on stable adhesion (p < 0.01 in each case). ** = p < 0.01 by Bonferroni test. (e), (f) Effects of function-blocking antibodies on
transient capture events (e) or stable adhesion (f) of PMN perfused over surfaces coated with PEV. Coated surfaces were pre-treated with anti-CD62P (n = 4),
or PMN were pre-treated with anti-CXCR1 (n = 4), anti CXCR2 (n = 4), or both (n = 3). Data are shown as percent of values without antibody. Not all
treatments were used in all experiments, but untreated controls were tested in each experiment. * = p < 0.05 compared to control by paired t test. All data are
mean ± from n experiments.
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the number had decreased by 24 h incubation (Fig. 6c). Firm
adhesion of PMN increased after 1-h pre-incubation with
PEV, increased further at 4 h, and then decreased by 24 h
(Fig. 6d). These results support the concept of two phases of
response to PEV by ECs, but indicate that over prolonged
incubation, capture and stimulation of firm adhesion wane.
We also tested the effects of PEV treatment of HUVEC
in the presence of increasing concentrations of TNF. TNF
treatment alone did not induce short-lived capture events, but
did cause dose-dependent increase in firm adhesion (Fig. 6e,
f). PEV caused many transient attachments for HUVEC
treated with 0- or 1-U/ml TNF, but few of these events were
observed for 5 U/ml (Fig. 6e). PEV increased firm adhesion
significantly only for the otherwise untreated HUVEC; at
1 U/ml TNF, there was a slight but not significant increase
in adhesion with PEV, but not at 5-U/ml TNF (Fig. 6f). In two
experiments with 100-U/ml TNF, transient capture events
were not observed with or without PEV, and incubation with
PEV did not alter the already very high levels of stable
adhesion (data not shown). This data suggests that PEV can
initiate PMN recruitment but have little extra effect for EC
stimulated by cytokines above a low level.
Further investigations aimed to dissect the mechanisms
promoting PMN interactions with HUVEC treated with PEV
for 4 h. Treatment of HUVEC with antibody against CD62P
after earlier incubation with PEV reduced transient attach-
ments and stable adhesion by about 80 and 60%, respectively
(Fig. 7a, b). Similar levels of inhibition were obtained if the
HUVEC were treated with antibody against E-selectin
(Fig. 7a, b). Blockade of CD54 (ICAM-1) did not inhibit
transient capture but did reduce the level of firm adhesion by
56%, while blockade of CD106 (VCAM-1) did not have
significant effects on capture or firm adhesion (Fig. 7a, b).
We also tested mechanisms which activated PMN after
HUVEC had been treated with PEV. Blockade of CXC
receptor 1 or 2 on PMN significantly reduced PMN capture
and adhesion by about 75%, with similar effect when both
were blocked (Fig. 7c, d). In addition, incubating HUVEC
cultures with blocking antibody against CXCL5 reduced
PMN firm adhesion by nearly 50%, but did not reduce inflow
capture significantly (Fig. 7c, d). Overall, these results suggest
that selectins provided or induced by PEV supported capture,
while stabilization of adhesion arose from activation through
CXC-chemokines.
Binding and Bioactivity of PEV Sub-populations for
PMN
We tested the ability of PEVlarge or PEVsmall fractionated
from PEV from CD41- or PKH-labeled platelets to bind and
label PMN. PEV and PEVlarge gave similar levels of PMN
label for either CD41 or PKH67 (~ 70 or ~90% positively
labeled, respectively) (Fig. 8a, b). PEVsmall on the other hand
only yielded ~ 10% labeled PMN for CD41, but ~ 40% for
PKH (Fig. 8a, b). The smaller PEV may not carry sufficient
CD41 to provide detectable label, but apparently carry
enough of the non-specific membrane label to make binding
to PMN detectable. We also observed that CD11b expression
was increased for PMN incubated with PEVlarge or PEV, but
not with PEVsmall (Fig. 8c). The different fractions were also
coated on microslides, and their ability to directly capture and
cause adhesion of PMN was tested. PEVlarg were highly
effective in capture and also more effective than unfractio-
nated PEV in causing stable adhesion of PMN (Fig. 8d, e). In
contract, PEVsmall were ineffective for either forms of
recruitment.
Fig. 5. Chemokines detected in vesicles suspensions or filtrates. PEVor filtrates obtained from PEVusing 0.2-μm pore filters or 100-kD MW cutoff filters
were analyzed by multiplex bead immunoassay measuring CXCL1/GRO-α, CXCL5/ENA-78, CXCL8/IL-8. * = p < 0.05, ** = p < 0.01 compared to PEV
by paired t test. Data are mean ± SEM from (n) experiments shown above each bar. Not all filtrates were tested in every experiments, but PEVwere tested in
each experiment.
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DISCUSSION
Extracellular vesicles released from activated platelets
have been shown to interact with leukocytes and ECs and
thereby modulate inflammation [41, 42]. However, their
precise roles in promoting capture and activation of flow-
ing PMN by endothelium have not been fully dissected to
date. Here, PEV were isolated from platelets activated by
collagen-related peptide (CRP-XL) and found to bind
efficiently to PMN or to EC. They were also able to
activate these cells as evidenced by increased expression
of adhesion molecules (e.g., CD11b or ICAM-1, respec-
tively). Interestingly, when PEVwere deposited on an inert
surface, they were able to directly capture flowing PMN,
supporting large numbers of short-lived attachments that
were occasionally converted to stable adhesion. Treatment
of otherwise-unstimulated EC with PEV also caused ap-
pearance of multiple short-lived attachments and an
Fig. 6. Ability of PEV to promote recruitment of flowing PMN byHUVEC. (a) Comparison of the number of transient capture events for PMN perfused at a
wall shear stress of 0.5 Pa over untreated HUVEC or HUVEC pre-treated with PEV for 1 h. Neutrophils were perfused alone (n = 9) or with PEVadded to the
cell suspension (n = 4). (b) Stably adherent PMN on HUVEC after perfusion as above, and washout of non-adherent cells. One-way ANOVA showed a
significant effect of treatment combinations on capture events and stable adhesion (p < 0.01 in each case). * = p < 0.05, ** = p < 0.01 compared to untreated
EC by Dunnett test. (c), (d) Effect of varying time of incubation of PEVwith HUVEC on transient capture events (c) or stable adhesion (d) of PMN perfused
over HUVEC at wall shear stress of 0.05 Pa (n = 6, 11, or 3 for incubation of 1, 4, or 24 h). One-way ANOVA showed significant effect of PEV incubation
(p < 0.01 in c, p < 0.05 in d). ** = p < 0.01 compared to untreated EC by Dunnett test. (e), (f) Effect of adding PEV to HUVEC treated with different
concentrations of TNF for 4 h, on transient capture events (e) or stable adhesion (f) of PMN perfused over HUVEC at wall shear stress of 0.05 Pa (n = 7, 5, 4
for 0, 1, or 5-U/ml TNF). ** = p < 0.01 compared to HUVECwithout PEV, tested separately at each TNF concentration, by paired t test. All the data aremean
± SEM from n experiments.
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increase in stable attachments, with the stable adhesion
more prominent after treatment for 4 h than after 1 h. These
effects were still evident if the EC had been treated with a
low dose of TNF (1 U/ml), but were not detectable among
the high levels of capture and activation of PMN which
occurred when the EC were pre-treated with 100 U/ml
TNF. PEV preparations could be divided into larger plate-
let microvesicles and smaller vesicles enriched in exo-
somes, and soluble agents present in the suspending medi-
um. Separation of the fractions by centrifugation or filtra-
tion indicated that the effects of PEV could be attributed
largely to the platelet microvesicles, which even carried
most of the chemokines found in the PEV preparation.
The number and diameter of vesicles from about
50 nm upwards were quantified by nanoparticle tracking
analysis. Their binding to PMN or EC was quantified by
flow cytometry, using PEV released by platelets that had
been pre-labeled with fluorescent antibody against CD41
(αIIb-integrin) or the non-specific membrane dye PKH67.
Flow cytometry could only detect the larger vesicles, but
showed that the great majority were labeled by these meth-
ods and allowed dynamics of the increasing binding to
target cells to be investigated. PMN rapidly bound PEV
and upregulated their expression of CD11b in a dose- and
time-dependent manner. The binding itself was Ca++-
dependent and attributable largely to CD62P (P-selectin)
and stabilized by CD11b. About half of EC became labeled
by PEV within 1 h and activation over 4 h was evidenced
by increases in expression of adhesion molecules, VCAM-
1, ICAM-1, and E-selectin. The binding was again Ca++-
dependent but not through P-selectin in this case. Several
classes of integrins contributed to binding in an RGDS-
dependent manner. The activatory responses observed are
largely consistent with previous studies of PMN [22] and
EC [12] incubated with platelet Bmicroparticles.^ P-
selectin has been widely shown to support interaction of
PMN with platelets [35, 39, 43], although it appeared to be
a minor player in interactions with PEV in one study [12].
Fig. 7. Mechanisms by which PEV promote recruitment of flowing PMN by HUVEC. (a), (b) Effects of blocking adhesion receptors on HUVEC after
incubation for 4 h with PEV, on transient capture events (a) or stable adhesion (b) of PMN perfused over HUVEC at a wall shear stress of 0.05 Pa. HUVEC
were treated with anti-CD62P (n = 6), anti-CD62E (n = 4), anti-CD54 (n = 4), or anti-CD106 (n = 4). (c), (d) Effects of blocking receptors on PMN or
chemokine CCL5 on HUVEC on transient capture events (c) or stable adhesion (d) of PMN perfused over HUVEC treated with PEV for 4 h. PMN were
treated with anti-CXCR1, anti-CXCR2, or both (each, n = 3), or HUVEC was treated with anti-CXCL5 (n = 4). Not all treatments were used in all
experiments, but untreated controls were tested in each experiment. All data are mean ± SEM from n experiments expressed relative to control without
antibodies. * = p < 0.05 compared to control by paired t test.
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Mechanisms of adhesion of PEV to ECs have not been
described before to our knowledge, although the platelet
αvβ3-integrin receptor has been implicated in RGDS-
dependent binding of intact platelets to HUVEC [44].
The ability of PEV to directly capture flowing leu-
kocytes has not been described before. The interactions
with PMN, although transient, resulted in the firm adhe-
sion of a small proportion of the cells perfused at a wall
shear stress of 0.1 Pa. The interactions were greatly
reduced if deposited PEV were treated with antibody
against P-selectin. Decreasing the shear stress from
0.1 Pa resulted in increased rates of capture, but more
evidently, in the numbers becoming firmly adherent. For-
low et al. [12] demonstrated that platelet microparticles
induced an increase in interaction between flowing leuko-
cytes and other surface-bound leukocytes through P-selec-
tin, but did not study capture by PEV alone. If PEV were
added to PMN and perfused over PEV-coated surfaces,
Fig. 8. Binding of different vesicles fractions to PMN and ability to support PMN recruitment from flow. (a) Percentage of PMN positively stained after
incubation for 30 min with PEV, PEVlarge or PEVsmall derived from platelets labeled with anti-CD41 (n = 5 for all treatments). (b) Percentage of PMN
positively stained after incubation for 30 min with PEV, PEVlarge, or PEVsmall derived from platelets labeled with PKH67 (n = 3 for all treatments). In (a) and
(b), one-way ANOVA showed significant effects of treatments (p < 0.01). ** = p < 0.01 compared to control without added PEV by Dunnett test. (c) Surface
expression of CD11b on PMN after incubation for 30 min with PEV, PEVlarge, or PEVsmall determined by MFI (n = 5 for all treatments). One-way ANOVA
showed a significant effect of treatment (p < 0.05) and borderline significance compared to control without added PEV byDunnett test for PEV (p = 0.06) and
PEVlarge (p = 0.07). (d) Transient capture events for PMN perfused at a wall shear stress of 0.1 Pa over surfaces coated with PEV, PEVlarge, or PEVsmall (n = 4
for each surface). One-way ANOVA showed significant effect of treatment (p < 0.01). ** = p < 0.05 compared to PEV by Dunnett test. (e) Stably adherent
PMN on surfaces coated with PEV, PEVlarge, or PEVsmall, after perfusion under the same conditions (n = 4 for each surface). One-way ANOVA showed
borderline significant effect of treatment (p = 0.054). All data are mean ± SEM from n experiments.
Inflammatory Activity of Platelet Extracellular Vesicles
capture and especially stable adhesion were increased over
levels for PMN perfused alone over the coated surface.
This was likely due to the activation of the perfused PMN
by the addition of PEV, thus increasing their firm adhesion
to the deposited PEV.
We also tested if PEV could directly mediate PMN
recruitment on HUVEC from flow, and/or whether pro-
longed incubation could have an indirect effect through
endothelial activation.We observed that PEV promoted the
transient capture of flowing PMN by otherwise unstimu-
lated EC. If PEV were added only to perfused PMN,
capture was as effective as if the EC had been pre-treated
with PEV. Indeed, pretreatment of EC for 1 or 4 h had
similar effects on capture from flow. Thus, it appears that
PEV can quickly induce capture events without regulation
of endothelial receptors. Longer 4-h incubations of EC
with the PEV did increase stable adhesion of PMN, sug-
gesting activation of the EC. After 24-h incubation, capture
events had decreased markedly and stable adhesion also,
suggesting that surface presented receptors from the PEV
had been lost or absorbed, and the activatory response had
waned. Interestingly, antibody blocking studies showed
roles for CD62E (E-selectin) as well as P-selectin in cap-
ture from flow, supporting the concept of a dual role for
direct (P-selectin) and indirect (E-selectin upregulation)
effects of PEV after prolonged treatment of EC. Stable
adhesion required the selectin-mediated capture and was
itself supported by CD54 (ICAM-1), which we had earlier
demonstrated to be upregulated by PE by flow cytometry.
Apart from supplying P-selectin to promote capture,
the PEV had stimulatory capacity for PMN. Indeed,
platelets are a rich source of chemokines, and of these,
PEV have been shown to deliver CXCL5 (ENA-78) at
least [45–47]. Blockade of CXCR1 and CXCR2 on PMN
inhibited firm adhesion, but not capture, on surface
bound PEV, suggesting that PMN activation occurred
through these receptors. We thus screened PEV for
CXCL1, 5 and 8. All were detectable, with CXCL5
having the highest concentration. Passage of PEV sus-
pension through a 100-kD cutoff filter greatly reduced
concentrations of the chemokines. Since their molecular
weights are ~ 10 kD, they were mainly associated with
the vesicles rather than in solution. Filtration though 0.2-
μm pore filters did not reduce levels of CXCL1, but did
reduce CXCL5 and CXCL8, indicating that the larger
PMV carried a proportion of the latter chemokines at
least. However, it should be noted that nanoparticle track-
ing analysis indicated that > 90% of vesicles were below
0.2 μm in diameter, and these vesicles could clearly carry
significant levels of chemokines.
PMN capture could also be transformed to firm adhe-
sion on EC which had been treated for PEV for 4 h. In this
case, treatment of PMN with function-blocking antibodies
against CXCR1 or CXCR2 or both decreased capture and
stable adhesion of the PMN. Blocking CXCL5 (the chemo-
kine found with highest concentration in PEV) on the EC
had a non-significant effect on capture but significantly
reduced stable adhesion. The conversion to stable adhesion
may have been through CXCL5 transferred to EC by PEV,
as well as chemokines generated by EC after activation by
PEV. The effect of blocking the chemokine receptors on
PMN on the transient capture events was not expected, as
no ability to support initial adhesion has been reported for
these receptors before. When ECwere treated with increas-
ing concentrations of TNF along with PEV, the effects of
the PEV on capture and stable adhesion decreased. Thus,
transfer of receptors or activating agents to the EC became
outweighed by the response of the EC to TNF, which
would induce increasing upregulation of selectins, CXC
chemokines, and ICAM-1 [48, 49].
Our study also gave insight into the relative bioactiv-
ities of the vesicular constituents of PEV. When PMVand
Pexo were enriched by centrifugal methods, PMV were
able to transfer much higher levels of CD41 to PMN than
the fraction enriched with exosomes. They also transferred
more of the non-specific membrane label PKH67, although
the small vesicle fraction did transfer this label as well. It
was also notable that only larger vesicles activated PMN to
upregulate CD11b expression, and when coated on a sur-
face, only they were able to support capture and stable
adhesion of flowing PMN. Thus, while both PMV and
Pexo could bind to PMN, transfer of surface receptors
was more effective for larger vesicles, and the ability to
directly induce PMN activation or support recruitment
from flow was restricted to them. Proteomic analysis has
previously demonstrated that PMVand Pexo have different
composition and content of platelet markers [34]. Howev-
er, we are not aware of studies of their differential effects
on leukocytes.
In summary, we have demonstrated that PEV can
directly activate PMN and also support a two-step recruit-
ment process through delivery of selectins and chemokines
to a surface. PEV can also activate EC to promote PMN
adhesion. Although this response is not as great as that
induced by high concentrations of TNF, it may potentiate
lower level stimuli. Generation of PEV is associated with a
range of thrombotic and inflammatory pathologies [5–7],
and our results support the concept that their levels are not
only markers of events, but will also influence their
outcome.
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